7 March 2019

Deviating from the treatment guideline for the orphan drug eculizumab for patients with aHUS has saved 17 million euros in healthcare costs. This has been shown by the doctoral study of Kioa Wijnsma, theme Renal disorders, which she will defend on 8 March. The results of her study pave the way for more research into reducing the costs of administering expensive drugs to treat rare diseases.

The lives of patients with atypical hemolytic uremic syndrome (aHUS), a severe kidney disease, changed drastically with the availability of the orphan drug eculizumab in 2011. Eculizumab is a very effective drug, but also one of the most expensive in the world. According to the manufacturere, the drug must be administered every two weeks for life, which costs up to €500,000 per patient per year. However, there is hardly any scientific substantiation of this recommended dosage and use of the product. 

Dose reduction

Kioa Wijnsma discovered that the levels of the drug in the blood of patients that were treated with exulizumab according to the manufacturer’s instructions were seven times higher than necessary. A small-scale study of 20 patients showed that the dose could be drastically reduced. In 17 of the patients, the treatment could be stopped entirely. The other three patients received a reduced dose. In five patients, the aHUS returned after some time, after which the treatment was resumed and could later be stopped again. This did not result in chronic kidney damage. 

Cost reduction

Since the amendment of the Dutch guideline in 2016 according to Wijnsma's insights, over €17 million in healthcare costs have been saved. According to data from the Dutch Healthcare Authority, the expenditure on such expensive drugs amounted to more than €2 billion in 2017. In terms of total costs per patient for such drugs, eculizumab is in sixth place. According to Wijnsma, her study can serve as an example for research into more efficient use of other orphan drugs, independent from the pharmaceutical industry: “Collaboration between patient organizations and medical specialists makes it possible to develop a unique, modified treatment scheme and to evaluate it together on the basis of a national study.” 

CUREiHUS study

For patients with aHUS, eculizumab treatment is now reimbursed by their health insurance as part of an ‘orphan drug arrangement’. A prerequisite for this arrangement is that the patients participate in the CUREiHUS study. The aim of this study is to select the most optimal dose for all patients. The researchers also look for markers in the blood that can predict whether an aHUS patient will relapse if treatment is stopped. A definitive cost-effectiveness analysis will take place after completion of the CUREiHUS study in 2020. 

About aHUS

In aHUS, the complement system, part of the immune system, is disrupted. This complement system is activated in response to infections, but in people with aHUS this system remains permanently active. This causes damage in the body, including the small blood vessels in the kidney. This can eventually lead to chronic kidney failure. However the disease is extremely rare. In the Netherlands, about five children and 15 adults are diagnosed with aHUS annually. Most patients have a genetic predisposition for the disease.
 

Related news items


Research Integrity Round 16 September 2020 Sex and gender and research integrity: a tale of how and who

9 July 2020

Topic of this webinar is sex and gender in (bio)medical research. Speakers are dean Prof. Jan Smit, Prof. Sabine Oertelt–Prigione and Prof. Hanneke Takkenberg (ErasmusMC). All junior and senior researchers are invited to join the discussion. Please register via the website.

read more

Finally, an explanation for hearing loss in twelve Dutch families

9 July 2020

The culprit is a genetic abnormality, a discovery that immediately makes it one of the most common causes of hereditary hearing loss in the Netherlands.

read more

Symposium ENABLE 2020 postponed to spring 2021

9 July 2020

Considering the COVID-19 pandemic, the ENABLE team decided to postpone the symposium to spring 2021!

read more

Rebecca Halbach receives idea generator grant to fight mosquito transmitted viruses

8 July 2020

Rebecca Halbach and Pascal Miesen have investigated in a collaborative project whether the treatment of mosquitoes with antiviral drugs can prevent the transmission of mosquito-transmitted viral diseases.

read more

Invasive fungal infections in influenza and COVID-19

8 July 2020

The Aspergillus fungus is found in the lungs of many COVID patients. A parallel occurs with influenza patients, who often develop a serious fungal infection. Although such a serious fungal infection seems to occur less frequently in COVID-patients, alertness remains necessary,

read more

Werner Koopman 25 years at Radboudumc celebrating online

8 July 2020

Werner Koopman completed his 25 years at Radboudumc. Biochemistry sent him a cake at home and celebrated this special moment during COVID-19 in a unique way.

read more